Zydus Cadila gets USFDA nod to market muscle spasms tablets

Image
Press Trust of India New Delhi
Last Updated : Apr 18 2020 | 1:18 PM IST

Drug firm Zydus Cadila on Saturday said it has received final nod from the US health regulator to market Baclofen tablets, used for treatment of muscle spasms caused by some conditions, in the American market.

The company has received final approval from the United States Food and Drug Administration (USFDA) to market Baclofen tablets in the strength of 5 mg, Zydus Cadila said in a statement.

The product will be manufactured at the group's formulations manufacturing facility at Baddi, it added.

Baclofen is used to treat muscle spasms caused by certain conditions such as multiple sclerosis and spinal cord injury/disease. It works by helping to relax the muscles, Zydus Cadila said.

The group now has 288 approvals and has so far filed over 386 abbreviated new drug applications (ANDAs) since the commencement of its filing process.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 18 2020 | 1:18 PM IST

Next Story